The therapeutic efficiency of hydroxichloroquine in the treatment protocol of COVID19 can be proven by the cure rate of patients in Cameroon which stands at 91.2%.
The Minister of Public Health, Dr Manaouda Malachi presented the result to the inter-Ministerial Committee in charge of evaluating and monitoring the implementation of the Government’s response strategy against the COVID-19 pandemic in Cameroon chaired by the Prime Minister, Head of Government, Joseph Dion Ngute.
At the end of the committee’s meeting of Thursday, August 13, 2020 it was resolved that Cameroon will continue hydroxichloroquine as part of the treatment protocol for COVID-19 in spite of some health bodies calling for a stop.
The Minister of Public Health however emphasised that scientific research continues and cases are being studied to assess the side effects of this medication.
WHO and FDA Call for a Halt in Use of Hydroxichloroquine
After the recommendation from the Solidarity Trial’s International Steering Committee to discontinue the trials of hydroxychloroquine and lopinavir/ritonavir arms, the WHO in July 2020 called for a stop in the use of Hydroxichloroquine as COVID-19 treatment.
The trial results show that hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care.
The Food and Drug Administration is of a similar view with the WHO.
The FDA’s statement indicates that cases of serious heart rhythm problems, blood and lymph system disorders, kidney injuries and liver problems and failures amongst others have been reported following the use of Hydroxichloroquine.
Eleanor Ayuketah Ngochi